Navigation Links
Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer
Date:9/10/2009

r earlier
  • The reaction was mild in most patients, resolving in 1 to 2 weeks
  • The reaction can be severe and debilitating in some patients, resulting in discontinuation of therapy
  • DOXIL is an irritant, not a vesicant; use precautions to avoid extravasation
  • DOXIL can cause fetal harm when used during pregnancy
  • Recall reaction has occurred with DOXIL administration after radiotherapy
  • DOXIL may interact with drugs known to interact with the conventional formulation of doxorubicin HCl
  • In patients with recurrent ovarian cancer, the most common all-grade adverse reactions (ARs) >20% (DOXIL vs topotecan, respectively) included: asthenia (40% vs 51%), fever (21% vs 31%), nausea (46% vs 63%), stomatitis (41% vs 15%), vomiting (33% vs 44%), diarrhea (21% vs 35%), anorexia (20% vs 22%), dyspnea (15% vs 23%), HFS (51% vs 1%), and rash (29% vs 12%)
    • In addition, 19% vs 52.3% reported alopecia (all grades)
    • Grade 3/4 hematologic ARs reported in >5% (DOXIL vs topotecan, respectively) were neutropenia (12% vs 76%) and anemia (6% vs 29%)
  • In patients with multiple myeloma, the most common all-grade ARs >20% (VELCADE plus DOXIL vs VELCADE, respectively) included: neutropenia (36% vs 22%), thrombocytopenia (33% vs 28%), anemia (25% vs 21%), fatigue (36% vs 28%), pyrexia (31% vs 22%), asthenia (22% vs 18%), nausea (48% vs 40%), diarrhea (46% vs 39%), vomiting (32% vs 22%), constipation (31% vs 31%), mucositis/stomatitis (20% vs 5%), peripheral neuropathy (42% vs 45%), neuralgia (17% vs 20%), and rash (22% vs 18%)
    • In addition, 19% vs <1% reported HFS
  • In patients with AIDS-related Kaposi's sarcoma, ARs reported in greater than or equal to 5% of DOXIL-treated patients were: neutropenia (ANC <1000/mm3, 46%; <500/mm
    '/>"/>

  • SOURCE Centocor Ortho Biotech Products, L.P.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
    2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
    3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
    4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
    5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
    6. GeneNews provides Centocor access to its osteoarthritis program
    7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
    8. Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
    9. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
    10. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
    11. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... Mass. , Aug. 31, 2015  RXi ... company focused on discovering and developing innovative therapies ... today announced that the 30-day review period following ... (IND) for ocular indications with the U.S. Food ... IND is now active. Logo ...
    (Date:8/31/2015)... , Aug. 31, 2015 LabStyle ... Diabetes Management Solution, today announced it recently closed ... Funds will be used to support the global ... Dario, a mobile, cloud-based, diabetes management solution that ... ,all-in-one, pocket-sized, blood glucose monitoring device, and for ...
    (Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive ... commercially available new FDA approved system in the last 14 years, and the only ... Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and ...
    (Date:8/28/2015)... 2015 According to a new ... Storage Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, ... End User - Global Forecast to 2020", published by ... USD 3,731.03 Million by 2020 from USD 2,150.48 Million ... 2015 and 2020. Browse 74 Tables ...
    Breaking Biology Technology:RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5
    ... researchers have made a breakthrough in understanding the effect ... pollution. The discovery could lead to more accurate forecasting ... Anderson. , Crozier is an associate professor in ASU,s ... College of Liberal Arts and Sciences and the Ira ...
    ... Verenium Corporation,(Nasdaq: VRNM ), a leading developer ... development of high-performance specialty enzymes, announced,today that Gerald ... at,the upcoming Canaccord Adams 28th Annual Global Growth ... a.m. ET on Thursday, August 14,and will take ...
    ... Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced today that ... an update on the company,s business,at the Thomas Weisel ... a.m. (Eastern Time) at the Four Seasons Hotel in ... the subsequent archived,recording, log on to http://www.monogrambio.com ...
    Cached Biology Technology:Forward step in forecasting global warming 2Forward step in forecasting global warming 3Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference 2Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference 3Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008 2
    (Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
    (Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
    (Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
    Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
    ... Tampa, Fla. (Dec, 19 2011) A ... into rats modeled with amyotrophic lateral sclerosis (ALS), ... lethal, neuromuscular disease, have tested four different immunosuppressive ... therapeutic effects. Their study demonstrated that a combined, ...
    ... Tampa, Fla. (Dec, 19 2011) Bone marrow-derived stem ... because they can contribute to different cell populations in a ... BMDC studies have been aimed at repairing damaged brain tissue ... focused on BMDC transplants to the cerebellum at the back ...
    ... disease drug discovery, MMV and SCYNEXIS, Inc. have assembled a ... antimalarial activity and will provide it to researchers at no ... confirmed activity against the blood-stage of P. falciparum ... were selected by experienced medicinal chemists from an extensive screening ...
    Cached Biology News:Grafting of human spinal stem cells into ALS rats best with immunosuppressant combination 2Bone marrow-derived cells differentiate in the brain through mechanisms of plasticity 2MMV and SCYNEXIS offer 400 active compounds for neglected disease drug research at no cost 2
    Mouse Activin RIB/ALK-4 MAb (Clone 207304)...
    ... 19 x 29 cm, 1. One ... staining of Coomassie Blue or silver-stain gels ... blots for high sensitivity ECL detection and ... volume, and processing time.Proven design for consistent, ...
    Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
    ... Reagent Pack, 1. Contains reagents for ... mouse and rabbit primary antibodies. Designed for ... reagents are not included, but the system ... Category: Blotting & Labeling & Detection, ...
    Biology Products: